跳转至内容
Merck
CN

I6658

Isradipine

≥98% (HPLC), calcium channel blocker, solid

别名:

4-(4-Benzofurazanyl)-1,-4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C19H21N3O5
化学文摘社编号:
分子量:
371.39
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

Isradipine, ≥98% (HPLC), solid

SMILES string

COC(=O)C1=C(C)NC(C)=C(C1c2cccc3nonc23)C(=O)OC(C)C

InChI key

HMJIYCCIJYRONP-UHFFFAOYSA-N

InChI

1S/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,16,20H,1-5H3

description

Store under nitrogen

assay

≥98% (HPLC)

form

solid

color

yellow

solubility

DMSO: >10 mg/mL

originator

Novartis

storage temp.

2-8°C

Quality Level

正在寻找类似产品? 访问 产品对比指南

Application

Isradipine has been used to explore neuroprotective activity.

Biochem/physiol Actions

Isradipine is considered as an active calcium channel blocker, used to treat hypertension.
L-type calcium channel blocker (also referred to as dihydropyridine-type calcium channel blocker); antihypertensive.
L-type calcium channel blocker; antihypertensive.

Features and Benefits

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Vincent Malaterre et al.
Drug development and industrial pharmacy, 35(4), 433-439 (2008-11-08)
Push-pull osmotic systems have been developed to deliver poorly soluble drugs in a modified-release fashion. The aim of this study was to investigate the influence of the tablet core factors on the drug release kinetics and loadability. The release kinetics
Philip F Copenhaver et al.
Disease models & mechanisms, 4(5), 634-648 (2011-05-21)
A growing body of evidence supports the 'calcium hypothesis' of Alzheimer's disease (AD), which postulates that a variety of insults might disrupt the homeostatic regulation of neuronal calcium (Ca(2+)) in the brain, resulting in the progressive symptoms that typify the
C Savio Chan et al.
Movement disorders : official journal of the Movement Disorder Society, 25 Suppl 1, S63-S70 (2010-02-27)
Parkinson's disease (PD) is a common neurodegenerative disorder of unknown etiology. There is no cure or proven strategy for slowing the progression of the disease. Although there are signs of pathology in many brain regions, the core symptoms of PD
Tanya Simuni et al.
Movement disorders : official journal of the Movement Disorder Society, 25(16), 2863-2866 (2010-09-08)
Recent data suggests that isradipine, a dihydropyridine calcium channel blocker, is neuroprotective in preclinical models of parkinsonism. Isradipine has not been systematically studied in patients with Parkinson's disease (PD). The aim of this study was to evaluate safety and tolerability
Invasomes of isradipine for enhanced transdermal delivery against hypertension: formulation, characterization, and in vivo pharmacodynamic study
Qadri G R, et al.
Artificial Cells, Nanomedicine, and Biotechnology (Print), 45(1), 139-145 (2017)

相关内容

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持